Dural Graft Market: Where a New Collagen Brand Can Compete

A new collagen dural graft brand rarely wins on the material alone. Most buyers already have a collagen option on contract. Where a newcomer can compete is everything around the material: a technique-matched range, simple stocking, complete documentation, responsive manufacturer support and a distributor who knows the accounts. That is the space DESU was built for.

This article looks at the dural graft category the way a distributor or an independent neuro agency has to look at it before committing sales time. It does not try to size the market or predict share. It maps the segments, the decision makers, the incumbent advantages and the openings that remain for a manufacturer that is new to an account.

How is the dural graft category segmented?

Surgeons who need to close or reinforce the dura have three broad families of material to choose from, and many departments use more than one. Adjuncts such as dural sealants sit alongside these grafts rather than replacing them, which is covered in our article on dural sealants and collagen grafts.

DESU competes in the second row. DURASHEET and DECOLL are both made from pure Type I bovine collagen, supplied in four sizes, ready to use and gamma sterilized. The practical question for a distributor is not whether collagen has a place, since it plainly does, but why a hospital would add or switch to one more collagen brand.

Who decides which dural graft a hospital stocks?

A dural graft is a physician preference item, but preference alone no longer gets a product onto the shelf. In most hospitals several groups have a say, and a distributor who speaks only to the surgeon tends to stall at the second or third step.

• Neurosurgeons and spine surgeons, who define the clinical requirement and must be willing to use the product.
• The value analysis committee, which weighs clinical need, cost per case and the overlap with products already on contract.
• Supply chain and contracting teams, which work within group purchasing and integrated delivery network agreements.
• OR materials managers and charge nurses, who care about par levels, storage, expiry and how many sizes must be stocked.
• Infection prevention and risk teams, who may ask about sterilization, animal origin and traceability.

Each of these groups needs a different piece of evidence. The surgeon wants to feel the graft in a case. The committee wants a short, honest comparison. Supply chain wants a clean item master and dependable lead times. A new brand that prepares for all of them looks far more serious than one that arrives with a brochure.

Where do incumbent brands have the advantage?

It is worth being candid about this, because an agency that underestimates the incumbents will burn months. Established dural graft brands usually hold three advantages that have little to do with the graft itself.

First, contract position: an item already on a group purchasing agreement or an IDN formulary is the default, and switching requires a reason. Second, habit: surgeons who have closed hundreds of cases with one graft know exactly how it behaves, and that familiarity has real clinical value. Third, coverage: incumbent reps are often in the OR every week, and the hospital has come to rely on that presence.

None of these advantages is permanent, but none disappears because a new product is cheaper. They are overcome by giving each decision maker a specific, low-risk reason to try something different.

Where can a new collagen brand realistically compete?

The openings tend to appear where incumbents are strong on paper but leave gaps in practice. In our experience of working with distributors across many markets, the following positions are the most credible for a new collagen brand.

As a technique-matched pair

Some surgeons suture a graft into the dural edge; others lay it over the defect as an onlay. DURASHEET is usable on both surfaces and suturable, while DECOLL is designed for onlay use. Offering both from one manufacturer lets a distributor match the graft to the surgeon’s technique instead of asking the surgeon to adapt.

As a second source

Supply interruptions and backorders have made many hospitals wary of single-sourcing implants. A qualified second collagen graft, already evaluated and on file, is a reasonable request for a value analysis committee even when the primary brand stays in place.

As a simpler stocking decision

Four sizes per product keeps the item master short. For a hospital that has accumulated many sizes across several brands, a compact range can be a genuine operational argument, especially when expiry losses on slow-moving sizes are already a concern.

As part of a neurosurgery portfolio

DESU also manufactures external drainage systems, catheters and shunts. A distributor who already serves a neuro-ICU with an EVD-010 Series system has a natural route into the same department’s OR, and one manufacturer relationship covers several product conversations.

As an accessible manufacturer

Large brands often route every question through several layers. DESU began in 2007 as an R&D company at Hacettepe Teknokent and still designs and manufactures in its own cleanrooms, so technical questions reach the people who make the product. For a distributor, that means faster answers on documentation, labeling and evaluation support, and a partner that is interested in building the line in a territory rather than simply shipping cartons.

Each of these positions is modest on its own. Together they give a value analysis committee a coherent story: a technique-matched collagen pair, simple to stock, backed by a quality system and a manufacturer that answers the phone.

Which accounts make realistic first targets?

Not every account is equally open to a new brand. The most promising first targets usually share one or more of the following traits: a department with both cranial and spine volume, a supply chain team actively looking for second sources, a surgeon who has expressed dissatisfaction with handling or sizing, or an existing relationship between the distributor and the neurosurgery service.

Large academic centers can be attractive because they run structured evaluations and influence regional practice, but their committees move slowly. Community hospitals with steady spine volume often decide faster and value a responsive local rep. A balanced pipeline usually includes both.

What does a credible entry plan look like?

A distributor adding a collagen dural graft line can shorten the path to the first order by preparing the work in a fixed sequence rather than improvising account by account.

• Map each target account’s dural graft use by procedure and by surgeon before the first meeting.
• Identify one surgeon champion whose technique fits DURASHEET or DECOLL naturally.
• Prepare a value analysis packet with product facts, quality certificates and an honest comparison.
• Agree a defined evaluation with the department, including sizes, number of cases and a feedback form.
• Line up the contract path with supply chain early, so a good evaluation does not wait months for paperwork.
• Plan service: who covers cases, how stock is replenished and how questions reach the manufacturer.

The manufacturer’s role in this plan is to make each step easier: supplying documents quickly, answering technical questions directly and supporting evaluations. That responsiveness is often the deciding factor between two otherwise similar collagen grafts.

Talk to a DESU product specialist

If you are a distributor, an independent neuro or spine agency, or a hospital team reviewing dural substitutes, DESU’s product specialists can walk you through DURASHEET and DECOLL, the documentation available and what partnership would look like in your market. Write to sales@desu.tr or use the contact page to start the conversation.